Showing results (91-100 of 223) with videos related to

Sort By:
Pageof 23
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 24, 2019
New antimicrobial options for the management of complicated intra-abdominal infectionsSebastiano Leone, Giovanni Damiani, Ilaria Pezone, et al.
Antiviral Therapy|April 29, 2022
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trialFranco Maggiolo, Nicola Gianotti, Laura Comi, et al.
Current HIV Research|May 17, 2007
Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAARTRenato Maserati, Andrea Foli, Lina Tomasoni, et al.
Antiviral Therapy|February 17, 2007
The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimensFranco Maggiolo, Diego Ripamonti, Carlo Torti, et al.
Microorganisms|February 26, 2025
Antimicrobial Lock Therapy in Clinical Practice: A Scoping ReviewAniello Alfieri, Sveva Di Franco, Maria Beatrice Passavanti, et al.
The New Microbiologica|February 5, 2010
Mycobacterium xenopi pulmonary infection resulting in self-limited immune reconstitution inflammatory syndrome in an HIV-1 infected patientSebastiano Leone, Sergio Giglio, Patrizia Maio, et al.
World Journal of Virology|October 7, 2020
Current status of COVID-19 treatment: An opinion reviewSveva Di Franco, Aniello Alfieri, Stephen Petrou, et al.
Plos Pathogens|May 30, 2009
Increasing clinical virulence in two decades of the Italian HIV epidemicViktor Müller, Franco Maggiolo, Fredy Suter, et al.
AIDS (London, England)|December 31, 2008
CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAARTFranco Maggiolo, Monica Airoldi, Annapaola Callegaro, et al.
Plos One|October 12, 2019
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemiaLucia Taramasso, Antonio Di Biagio, Niccolò Riccardi, et al.
Pageof 23